/* t2 */
🏆 Cámara Peruana de Comercio Exterior desde 2011 • ONGD inscrita en APCI (ENIEX) • Único miembro de IUCAB en Latinoamérica • Institución calificada por Google for Education • +40,000 alumnos entre matriculados y certificados Conoce nuestra historia
Live Briefing · Sem.6 día 3Vol. I · Núm. 033
MIÉ · 24.JUN.2026Lima — Perú07:45 UTC-5
C
CAMEX  ·  FDA SERVICES DIVISION
FDA Briefing
Diario.

Edición № 033. Sem.6 día 3 · Adverse Event Reporting deep-dive. Section 605 de MoCRA establece 15 business days desde awareness para reportar serious adverse events. Enforceable desde diciembre 2023 — 30+ meses ya active. La obligation con clock más tight de MoCRA. AEMS Public Dashboard transparente — competitors + plaintiffs monitoring tus AEs. 7 categorías de “serious” · records 6 años retention. Hoy: framework + 15-day clock dynamics + AEMS dashboard exposure + LatAm gaps comunes.

Edición
№ 033
CoberturaAER · Section 605
Foco15-day clock + AEMS
FormatoDoctrine + workflow
Próxima edición25.JUN.2026
Sem.6 · día 3 · the 15-day clock

Tras renewal countdown (031) + safety substantiation (032), hoy cerramos el trinity operativo MoCRA con Adverse Event Reporting. Section 605 es la obligation con clock más tight de MoCRA — 15 business days desde awareness. Y a diferencia de safety substantiation (Section 608 sin guidance), AER es operationally enforceable desde dic 2023. 30+ meses ya active. AEMS Public Dashboard hace tu data transparente. Competitor + plaintiff monitoring routine. Para LatAm: gap más comúnmente missing es internal capture system que feeds 15-day clock reliably.

U.S. FDA · MoCRA Section 605 · Serious Adverse Event Reporting · 15 Business DaysSECTION 605
Obligation
Section 605 · enforceable 2023
Clock
15 business days
Records retention
6 años · 3 small biz
Public Dashboard
AEMS · transparent
Adverse Event Reporting · Section 605 · 30+ meses active

15 business days. 30+ meses active. 7 categorías. Cero margen.

Section 605 de MoCRA establece la obligation con clock más tight de toda regulación cosmetics: 15 business days (3 weeks) desde awareness para reportar serious adverse events. A diferencia de safety substantiation (Section 608) que opera sin FDA guidance interpretativa, AER es operationally enforceable desde diciembre 29, 2023 — 30+ meses ya active. Form FDA 3500A via MedWatch program; email a CosmeticAERS@fda.hhs.gov; mail option available pero electronic strongly encouraged.

La definition de “serious” es estructurada en 7 categorías: (α) death, (β) life-threatening experience, (γ) inpatient hospitalization, (δ) persistent or significant disability/incapacity, (ε) congenital anomaly or birth defect, (ζ) infection, (η) significant disfigurement. La última categoría incluye serious rashes, second/third-degree burns, significant hair loss, persistent alteration of appearance — eventos comunes en cosmetics que many LatAm SME manufacturers historically tratan as customer service issues, no regulatory events. Esa misclassification es el gap structural más común. AEMS Public Dashboard makes reports searchable by anyone — competitors monitoring tu portfolio, plaintiffs’ bar tracking patterns, journalists writing stories. La transparency cambia game completamente.

15
business days clock
desde first awareness
7
categorías de “serious”
defined by FDA
6
años records retention
3 para small business
1
año follow-up window
new medical info

Las 5 noticias Section 605 del día

Selección Camex · Curado 24.JUN.2026 · 07:30
0115-day clock
15 business daysSection 605Enforceable 30+ meses

El 15-day clock: cuándo empieza · qué cuenta como “first awareness”.

El clock 15-business-day es operacionalmente complejo. La pregunta crítica: ¿cuándo exactly empieza? FDA’s interpretation: desde “first awareness” — el momento que cualquier persona en tu organización recibe information de un potential serious adverse event. Esto incluye: customer service rep en call center, social media manager que ve DM con foto de reaction, sales rep en retail que oye consumer complaint, QA team que recibe escalation, médico-call-center si tu organization usa one.

Implication operativa: el clock puede empezar antes de que tu regulatory team sepa. Si customer service team recibe email con AE notification el lunes pero no escalates hasta el viernes, technically clock empezó el lunes. Si social media post viral describe AE el miércoles pero tu team no ve hasta semana siguiente, technically clock empezó el miércoles si argumento “should have known” applies. “First awareness” interpretation tiende a broad post-MoCRA. Para LatAm operators, esto significa: capture system debe operar across all consumer touchpoints, not just regulatory team. Customer service, social media monitoring, retail feedback, healthcare provider reports — todos requires integrated funnel hacia regulatory team con clear handoff protocols + timestamp documentation.

“First awareness es desde que cualquier persona en tu organization sabe — no desde que regulatory team sabe. La interpretación broad es el default. Sin integrated capture system, gap structural automático.” — Camex · doctrina 15-day clock
▲ Impacto LatAm

LatAm operators sin integrated AE capture system: operationally exposed. Customer service Spanish-language teams en LatAm + Spanish-language consumer touchpoints en USA market. Multiple potential entry points: México call centers, Brasil customer service, USA importer feedback channels, Hispanic social media (Facebook, Instagram, TikTok español). Cada uno potential AE entry point. Sin captura sistemática + timestamp, defense durante FDA inspection challenged.

✓ Acción Camex recomendada

Integrated AE capture system audit para LatAm cosmetics: (α) identify all consumer touchpoints (CS, social, retail, healthcare), (β) train staff en AE recognition + immediate escalation protocol, (γ) timestamp documentation system, (δ) centralize en single regulatory tracking, (ε) bilingual capability ES/PT-EN. Camex articula AE capture system framework específico para LatAm.

Fuente: FDA AER framework Section 605 · MoCRA enforcement guidance · industry best practices · MedWatch Form 3500A · CosmeticAERS@fda.hhs.gov

15-day clock · timeline dynamics
★ DAY 0 · AWARENESSFirst awarenessCS rep · social · retail · QADAY 1-3Internal triage + escalationHand-off a regulatory teamDAY 4-7Classification “serious”7 categorías evaluationDAY 8-12Report drafting + reviewForm 3500A + product labelDAY 13-15Submission windowEmail/electronic preferred★ DAY 15+ · LATEViolation territoryProhibited act under FD&C
15-day clock dinámica: Day 0 desde cualquier touchpoint, no desde regulatory team awareness. Late submission = prohibited act.
02“Serious” def
Definition7 categoríasMisclassification gap

“Serious” definition: las 7 categorías que disparan obligation.

FDA defines “serious adverse event” en 7 specific categorías: (α) death; (β) life-threatening experience; (γ) inpatient hospitalization; (δ) persistent or significant disability or incapacity; (ε) congenital anomaly or birth defect; (ζ) infection; (η) significant disfigurement. La (η) significant disfigurement es la categoría más relevante operativamente para cosmetics — includes “serious and persistent rashes, second- or third-degree burns, significant hair loss, or persistent or significant alteration of appearance”, other than as intended under conditions of use.

El gap estructural típico LatAm: misclassification de events. Customer reports rash from face cream → tratado como customer service issue → refund + replacement product → archived. Pero si rash is “serious and persistent” (category η), el event requires 15-day FDA report. Similarly: chemical burn from hair smoothing product (often Brazilian smoothing treatments), significant hair loss from relaxer, persistent skin discoloration from skin lightening products, severe allergic reactions from fragrance compounds. Cada uno potential category η event. La interpretation de “serious” requires medical judgment — many LatAm operators conservatively under-report from caution. Pero under-reporting tiene exposure simétrica: si FDA inspector reviewing records identifies events que should have been reported, regulatory action follows.

“7 categorías. La (η) disfigurement es donde cosmetics live mayoritariamente. Rash, burn, hair loss, alteration of appearance. Misclassification es el gap más común — tratando como customer service lo que es regulatory.” — Camex · doctrina classification
▲ Impacto LatAm

LatAm cosmetics products en categorías high-AE-risk: hair smoothing treatments (Brazilian, keratin, formaldehyde-releasers) elevated burn + scalp damage risk; skin lightening products elevated discoloration + irritation risk; color cosmetics elevated allergic reaction risk; fragrance products elevated sensitization risk. Para cada categoría, classification training crítico para customer service + QA teams. Sin training, gap structural automático.

✓ Acción Camex recomendada

Classification training program para LatAm cosmetics operators: (α) staff training en 7 serious categorías recognition, (β) decision tree per event type, (γ) medical advisor consultation framework, (δ) documented classification rationale per event, (ε) annual training refresh. Investment 1-2 días training per team + ongoing reference materials. Camex articula classification framework + training.

Fuente: MoCRA Section 605 · FDA definition serious adverse event · 21 USC §364c(a)(2) · industry interpretation guidance

7 categorías · relevance cosmetics
FDA SERIOUS DEFINITIONα · Deathrareβ · Life-threateningrareγ · Hospitalizationmoderateδ · Disabilityuncommonε · Birth defectrareζ · Infectionmoderate★ η · Disfigurement★ DOMINANTη · DISFIGUREMENT INCLUDES• Serious and persistent rashes• Second/third-degree burns• Significant hair loss• Persistent alteration of appearance
Categoría η (disfigurement) es dominante para cosmetics. Rashes, burns, hair loss, alteration of appearance — todos qualify. Most common misclassification target.
03AEMS public
Public DashboardAEMS searchableTransparency change

AEMS Public Dashboard: tu data es transparente al público.

FDA opera el FDA Adverse Event Monitoring System (AEMS) Public Dashboard para Cosmetic Products — user-friendly, interactive web-based tool que da al público ability de query database de adverse event reports. Cualquier persona puede search por brand name, product name, ingredient, category, date range, severity. Esto es cambio fundamental vs pre-MoCRA reality cuando AE reports were FDA-internal data. Post-MoCRA: competitors monitorean tu portfolio AE patterns, plaintiffs’ bar correlates events para potential class action, journalists writing safety stories, consumers checking before purchase.

Para LatAm exporters, AEMS transparency tiene 3 implicaciones operativas: (α) competitive intelligence visible — tus AE patterns are competitor-readable, just as you can read theirs; (β) defensive monitoring required — tu organization should monitor AEMS por products vinculados a tu brand para identificar gaps en internal capture system (si FDA tiene report tu no recibiste, gap demostrado); (γ) reputational management proactive — public dashboard data feeds journalism + influencer reviews + consumer purchasing decisions. La transparency aligns incentives para better AE management. Quien manages well: public dashboard refleja low/no AEs. Quien manages poorly: dashboard becomes evidence of inadequate program.

“AEMS Public Dashboard cambia game completamente. Tu AE data is competitor-readable, plaintiff-readable, consumer-readable. Defense ahora requires not just compliance, sino brand reputation management active.” — Camex · doctrina AEMS transparency
▲ Impacto LatAm

LatAm cosmetics brands operating en USA: AEMS Dashboard transparency aplica equally a foreign brands. Reports filed against tu products by USA consumers, healthcare providers, retailers — todos visible publicly. Para LatAm brands con strong USA Hispanic market presence: Spanish-language consumer reports often filtered via Spanish-speaking healthcare providers or community channels. Monitor AEMS in English + check para tu brand mentions. Sin monitoring, blind spot estructural.

✓ Acción Camex recomendada

AEMS Dashboard monitoring routine para LatAm cosmetics: (α) monthly query AEMS por tu brand + competitor brands, (β) cross-reference contra internal AE database, (γ) identify gaps si FDA report no matches internal capture, (δ) trending analysis quarterly, (ε) integration con monitoring routine (cubierto № 023). Investment 1-2 horas/mes · zero cost FDA. Camex provee AEMS monitoring framework + integration.

Fuente: FDA AEMS Public Dashboard for Cosmetic Products · MoCRA Section 605 transparency · FDA Adverse Event Reporting System (formerly FAERS) · public access framework

AEMS Dashboard · who monitors what
DASHBOARD STAKEHOLDERSAEMS DASHBOARDPublic searchFDAReceives reportsCOMPETITORSIntelligencePLAINTIFFSClass actionCONSUMERSPurchase decisionJOURNALISTSSafety stories★ YOUDefensive monitor★ MONITOR YOUR DASHBOARD AS THEY DO
5 stakeholders monitorean AEMS Dashboard: FDA, competitors, plaintiffs, consumers, journalists. YOU should monitor it too — defensive intelligence.
046 años records
Records retention6 years standard3 years small business

Records: 6 años retention · más amplio de lo que parece.

MoCRA establishes 6-year records retention standard para AE-related documentation (3 años para small businesses). El scope de “AE-related records” es broader que solo submitted reports: incluye (α) all adverse event reports received (serious + non-serious + dismissed), (β) all complaint records (customer service logs, social media complaints, retailer feedback), (γ) seriousness assessments + documented rationale, (δ) follow-up medical information received, (ε) communications con FDA, (ζ) communications con consumers post-event, (η) corrective actions taken.

Para LatAm operators, la 6-year horizon tiene operational implications específicas: la mayoría LatAm cosmetics companies operan customer service systems con limited records retention — typically 1-3 años por practical reasons (storage costs, system limits). MoCRA effectively requires upgrade del records system para 6-year retention minimum. Plus: records must be accessible durante inspection. “Records exist” no es suficiente si tomar 2-3 horas to find them. FDA expectation: 30-60 minutos retrieval time. Sin centralized digital system con search/retrieval capability, inspection performance suffers — y AER records gap is one of most common findings durante MoCRA inspections.

“6 años records es no solo retention — es accessibility. Records que existen pero no son retrievables son operationally equivalent a records missing. Digital centralization is the only practical answer.” — Camex · doctrina records retention
▲ Impacto LatAm

LatAm cosmetics operators con customer service systems pre-MoCRA: most need records system upgrade. Multilingual records (Spanish + Portuguese + English) require integration. Customer service teams en multiple jurisdictions (México, Brasil, Centroamérica) require unified backend. Investment: $15K-50K para small-mid scale operations, $50K-200K para larger. Vs single inspection finding cost (potential warning letter + corrective action): $100K-500K+. Cost-benefit favorable.

✓ Acción Camex recomendada

Records system audit para LatAm cosmetics: (α) inventory existing AE-related records last 24 meses, (β) identify gaps en retention (typically pre-2024 records missing), (γ) implement digital centralization system, (δ) backup + redundancy para 6-year horizon, (ε) bilingual search capability ES/PT/EN, (ζ) annual records audit + verification. Camex articula records system upgrade roadmap específico.

Fuente: MoCRA Section 605 records retention · 21 CFR §700.4 · industry best practices · FDA inspection observations · Biorius guide

Records scope · 7 categorías retention
RECORDS REQUIRED 6 AÑOSα · All AE reports receivedβ · Complaint records (CS + social)γ · Seriousness assessments + rationaleδ · Follow-up medical informationε · Communications con FDAζ · Communications con consumersη · Corrective actions taken★ ACCESSIBILITY EXPECTATIONRetrieval time goal: 30-60 minutosStorage cost ~$10-50K/año · vs finding $100K-500K
7 record types required 6-year retention. Accessibility (30-60 min retrieval) es as important as existence. Digital centralization is the practical answer.
05US Responsible
Foreign exportersResponsible Person designationU.S. Agent role

Foreign exporters: Responsible Person designation mandatory.

Para LatAm cosmetics exporters serviendo USA market, MoCRA requires Responsible Person (RP) designation con USA-side accountability. La RP is the manufacturer, packer, or distributor of a cosmetic product whose name appears on the label. For foreign manufacturers without USA presence direct, RP designation typically requires: (α) USA-based importer or distributor que acepta RP responsibility, o (β) U.S. Agent designated por foreign manufacturer specifically para FDA matters.

La RP carries significant operational liability: receives serious AE reports, submits Form 3500A, maintains records 6 años, manages FDA inspections, coordinates recalls if needed. Para foreign exporter, RP relationship determines USA compliance posture completamente. Common LatAm models: (i) RP es el importer USA (low cost, dependent on importer relationship), (ii) RP es Camex o consultor regulatorio USA-based (independent, costo $5K-25K/año), (iii) RP es subsidiary USA del foreign manufacturer (high cost, full control). Para LatAm SMEs typically iniciando USA market, opción (ii) provides best cost-benefit. Sin RP designated, foreign cosmetic product is technically misbranded bajo Section 301(hhh) — same enforcement consequence que failed facility renewal.

“Foreign exporter sin USA-based RP designated = misbranded product. Mismo enforcement consequence que failed renewal. RP relationship determines USA compliance posture completamente.” — Camex · doctrina RP designation
▲ Impacto LatAm

LatAm cosmetics exporters operating sin clear RP designation: operational exposure significant. Common pattern: assumption que contract manufacturer USA-side handles “all FDA stuff” — pero RP responsibility legally specific. Verification: check tu product labels — whose name appears? That entity is the RP. Si no es tu brand: verify with that entity if they accept RP role. Si su tu brand: ensure RP responsibilities fulfilled by designated USA-side party.

✓ Acción Camex recomendada

RP designation audit para LatAm cosmetics exporters: (α) review tu products en USA market — whose name on label? (β) verify with that entity if RP responsibilities fulfilled, (γ) document RP agreement formally, (δ) ensure RP has AE capture + reporting capability + 6-year records system, (ε) annual review de RP relationship. Camex offers RP service para LatAm cosmetics exporters needing independent USA-side accountability.

Fuente: MoCRA Section 605 · Responsible Person definition · 21 USC §364b · Foreign Manufacturer Requirements · U.S. Agent framework

RP designation · 3 models LatAm
3 RP MODELS COMMONMODELO i · IMPORTER AS RPImporter USA accepts RP roleLow cost · dependent on relationship · most common LatAm★ MODELO ii · CONSULTANT RPCamex o consultor USA-basedIndependent · $5K-25K/año · best LatAm SMEMODELO iii · USA SUBSIDIARYSubsidiary del foreign manufacturerHigh cost · full control · larger LatAm onlySIN RP DESIGNATEDProduct misbranded · Section 301(hhh)Same enforcement = failed renewal
3 RP models common. Para LatAm SME, Modelo ii (consultant RP) provides best cost-benefit + independence. Sin RP = misbranded product.

Las 7 categorías de serious adverse event

FDA definition · 21 USC §364c

Cada categoría · su trigger · su relevance cosmetics.

Classification framework
α
DEATH

Death reportada

Death directamente attribuible al cosmetic product use. Rare en cosmetics pero historically documented (e.g., asbestos-contaminated talc cases). Automatic serious.

β
LIFE-THREATENING

Life-threatening experience

Acute anaphylactic reaction, severe respiratory distress, life-threatening allergic reaction. Less common pero documented en fragrance allergies, color cosmetics reactions.

γ
HOSPITALIZATION

Inpatient hospitalization

Severe burns from hair smoothing/relaxing requiring hospital treatment. Severe allergic reactions requiring observation. Chemical burns from misused products.

δ
DISABILITY

Persistent disability

Significant or persistent disability/incapacity. Eye damage from cosmetics, skin damage requiring ongoing treatment, severe contact dermatitis con long-term impact.

ε
BIRTH DEFECT

Congenital anomaly

Birth defect attributed to cosmetic use during pregnancy. Rare pero documented en research literature for specific ingredients (retinoids, hormone disruptors).

ζ
INFECTION

Infection caused

Bacterial, fungal, viral infection attributed al cosmetic. Contaminated mascara → eye infection. Contaminated topical → skin infection. Often vinculados a preservation failures.

η
★ DISFIGUREMENT

Significant disfigurement

Dominant cosmetics category. Includes serious + persistent rashes, 2nd/3rd-degree burns, significant hair loss, persistent alteration of appearance.

+
MEDICAL/SURGICAL

Intervention required

Plus any event requiring medical o surgical intervention para prevent one of the 7 outcomes above. Wider safety net incluyendo “would have been serious if not intervened”.

AER workflow · 5 pasos operativos

Desde awareness hasta submission

Internal workflow · receive → triage → classify → report → follow-up.

15-day clock distribution
α

RECEIVE · capture

Customer service receives AE notification. Social media monitoring flags potential AE. Retailer feedback escalates. Healthcare provider report received. Clock starts AQUÍ — Day 0.

Day0
β

TRIAGE · escalation

Capture team escalates a regulatory team via documented protocol. Timestamp documented. Initial information gathered: who reported, what happened, when, product involved, lot number if available.

Day1-3
γ

CLASSIFY · serious determination

Regulatory team evaluates contra 7 categorías. Medical advisor consultation si needed. Documentation de classification rationale. Decision: serious → 15-day report required; non-serious → recorded but not reported.

Day4-7
δ

REPORT · draft + review

Form FDA 3500A completed. Product label image attached. Medical information documented. Internal stakeholder review (regulatory + medical + legal). Final approval para submission.

Day8-12
ε

SUBMIT · FDA notification

Form 3500A submitted via electronic (preferred) o email CosmeticAERS@fda.hhs.gov. Confirmation received + documented. Records archived en 6-year retention system. Follow-up protocol activated for 1-year window.

Day13-15

AEMS Public Dashboard · transparency implications

Public access · stakeholder monitoring

Lo que cambia con AEMS Public Dashboard.

Operational transparency analysis
PRE-MoCRA · 2023-
$
Internal FDA data

AE reports were FDA-internal data. Not publicly accessible except via FOIA requests (slow, partial). Competitors no podían monitor real-time. Plaintiffs’ bar limited access. Consumer awareness minimal.

AccessFDA only · FOIA
Latency6-24 meses
StakeholdersFDA + foia requestors
POST-MoCRA · 2023+
★
Public dashboard searchable

AEMS Dashboard real-time searchable por anyone. Competitors monitor competitor patterns. Plaintiffs’ bar tracks events para class action potential. Consumers check before purchase. Journalists write safety stories.

AccessPublic · real-time
LatencyDays-weeks max
Stakeholders★ Everyone

5 gaps comunes LatAm · AER framework

Lo que Camex articula closing

Los 5 gaps structural más comunes LatAm en AER.

Camex defensive doctrine
α
CAPTURE SYSTEM

No integrated funnel

Customer service, social media, retail feedback, healthcare providers — multiple touchpoints sin centralized capture. AE notification can stuck en CS team semanas before reaching regulatory. Clock starts when CS received, not regulatory.

β
CLASSIFICATION

Misclassification endemic

Reaction events tratados as customer service issues + refund/replacement. Without 7-category training, rashes/burns/hair loss qualifying como “serious” pero classified como minor. Under-reporting structural automatic.

γ
RECORDS SCATTERED

No 6-year system

Records in email, file servers, multiple desktops, no centralized digital system. 6-year retention partially fulfilled (recent records exist, older missing). Inspection performance challenged. Retrieval time hours/days vs 30-60 min expected.

δ
RP UNCLEAR

No documented RP

Foreign exporter assuming importer USA o contract manufacturer handles AER. No formal RP designation documented. RP responsibilities (15-day reporting, records, FDA communications) not clearly delegated. Operational risk asymmetric.

ε
NO AEMS MONITOR

No defensive monitoring

AEMS Public Dashboard exists pero LatAm operator no monitors. FDA may receive AE reports about your products you never received internally — proving gap en capture system. Without monitoring, blind spot estructural.

★ INSIGHT CAMEX

Los 5 gaps operan en sequence: α (capture) gap leads to β (classification) gap leads to γ (records) gap leads to δ (RP) accountability blur leads to ε (no monitoring) blind spot. Closing requires integrated system, no piecemeal fixes. Investment: $30K-150K per organization scope. Vs single AE incident with regulatory consequence: $500K-5M+. Cost-benefit overwhelmingly favorable. Camex articula AER framework integrado con renewal compliance + safety substantiation + records system + RP designation.

15 días. 7 categorías. 6 años records. AEMS transparente.

Adverse Event Reporting es la obligation MoCRA con clock más tight + transparency public + operational enforceability desde diciembre 2023. 30+ meses ya active. Section 605 requires 15 business days desde first awareness, 7 categorías de “serious” defined, records 6 años retention, AEMS Public Dashboard searchable. Para LatAm cosmetics exporters, gaps structurales son comunes — particularly capture system integration, classification training, records centralization, RP designation, defensive monitoring. Sem.6 día 3 cierra trinity MoCRA operativo (Registration + Substantiation + AER). Próximas ediciones Sem.6: labeling + claims framework, cGMP Phase 2 preparation, sectorial deep-dives específicos LatAm. Camex articula end-to-end MoCRA compliance integrada.

33
Ediciones acumuladas en la serie
7 días
Hasta MoCRA renewal deadline
+ 200
Empresas articuladas con Camex
Camex · FDA Briefing · Sem.6 día 3 · AER deep-diveEdición № 033 · 24.JUN.2026 · Próxima: 25.JUN.2026Vol I · № 033

Leave A Comment

Your email address will not be published. Required fields are marked *

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.